Form 4: SoftBank Affiliate Sells Vir Bio Shares

SVF Endurance (Cayman) Ltd, an affiliate of SoftBank Vision Fund, sold 191,854 shares of Vir Biotechnology common stock for a weighted average price of $5.9826.

Summary

• SVF Endurance (Cayman) Ltd, a 10% owner of Vir Biotechnology, Inc. (VIR), disposed of 191,854 shares of common stock.
• The transaction occurred on December 1, 2025, at a weighted average price of $5.9826 per share, totaling approximately $1,147,300.04.
• The shares were sold in multiple transactions with prices ranging from $5.855 to $6.2794.
• Following this transaction, SVF Endurance (Cayman) Ltd beneficially owns 13,728,924 shares of Vir Biotechnology common stock indirectly.
• The sale was executed pursuant to a Rule 10b5-1 trading plan established by the Reporting Person on September 3, 2025.
• SVF Endurance (Cayman) Limited is a wholly-owned subsidiary of SoftBank Vision Fund (AIV M1) L.P., which is managed by SB Investment Advisers (UK) Limited.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a significant sale by a 10% owner. However, the fact that it was a pre-planned sale under Rule 10b5-1 mitigates some of the immediate negative implications compared to an ad-hoc sale.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled divestment rather than an immediate reaction to new information.

Negatives

• A significant sale of 191,854 shares by a 10% institutional owner, SVF Endurance (Cayman) Ltd, could be perceived as a negative signal regarding the company's future prospects.
• The transaction represents a reduction in the stake held by a major investor, potentially signaling reduced confidence or a strategic portfolio rebalancing.

Risks

• The sale by a major institutional investor could lead to negative market sentiment and potential downward pressure on Vir Biotechnology's stock price.
• Reduced institutional ownership might decrease the stock's liquidity or attractiveness to other large investors.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

The transaction reflects an institutional investor's portfolio management decision within the biotechnology sector. Such sales by major shareholders are common, particularly when executed under pre-arranged trading plans, but can still influence market perception of the underlying company.

Related Party Transactions

• The sale of common stock by SVF Endurance (Cayman) Ltd, a 10% owner of Vir Biotechnology, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the sale by a major institutional investor as a signal of reduced confidence, potentially impacting their investment decisions.
• The transaction could contribute to increased trading volume and potential price volatility for Vir Biotechnology shares.

Key Dates

Recommendation

The sale of shares by a 10% owner, even under a pre-arranged 10b5-1 plan, typically signals a lack of increasing conviction or a strategic portfolio adjustment rather than a strong positive outlook. While not an immediate 'sell' signal due to the planned nature of the transaction, it warrants caution. Investors should 'hold' and monitor future developments and the company's operational performance, as this divestment could indicate a ceiling on the institutional investor's valuation or a shift in their investment strategy.

Keywords

Vir Biotechnology, VIR, SoftBank, SVF Endurance, Stock Sale, Insider Transaction, Form 4, Biotechnology, Institutional Investor, 10b5-1 Plan